Clinical-Grade Genome Sequencing Standards In Russia.
1. Introduction
Clinical-grade genome sequencing in Russia refers to the legal, scientific, technical and professional standards governing the use of DNA sequencing technologies for medical diagnosis, disease-risk assessment, hereditary disease detection, cancer genomics, pharmacogenomics and personalised treatment.
Genome sequencing is different from ordinary genetic testing because it can examine a much larger proportion of an individual's genetic information. It may involve:
Whole Genome Sequencing (WGS).
Whole Exome Sequencing (WES).
Targeted gene-panel sequencing.
Next-Generation Sequencing (NGS).
Clinical tumour sequencing.
Prenatal and reproductive genetic testing.
Pharmacogenomic sequencing.
In Russia, clinical genome sequencing is governed by a combination of medical legislation, laboratory licensing requirements, quality-management standards, personal-data protection rules, informed-consent requirements and professional clinical recommendations.
An important legal distinction: Russia does not have one comprehensive statute establishing a separate, universally applicable clinical-grade whole-genome sequencing certification system. Instead, several legal instruments collectively regulate the clinical laboratory, the genetic investigation, the handling of patient information and the medical use of results.
The central legal challenge is ensuring that sequencing results are scientifically reliable, clinically interpretable, reproducible and obtained with appropriate patient consent.
2. Main Legislative Framework in Russia
The principal legislation and regulatory instruments include:
A. Federal Law No. 323-FZ of 21 November 2011 – Protection of Citizens' Health
The Federal Law on the Fundamentals of Health Protection of Citizens in the Russian Federation provides the general legal foundation for clinical genetic investigations.
Its important principles include:
The patient's right to medical care.
Informed voluntary consent.
Medical confidentiality.
Professional responsibility of healthcare practitioners.
Quality and safety of medical services.
Patient rights concerning medical information.
Under this framework, a genome sequencing procedure performed for medical purposes must be treated as part of healthcare delivery rather than simply as a commercial laboratory service.
Legal significance: A hospital or laboratory cannot justify an unreliable genetic diagnosis merely because sequencing technology was used. The investigation must be appropriately organised and its results must be medically meaningful.
B. Federal Law No. 152-FZ of 27 July 2006 – Personal Data
Genetic information can reveal highly sensitive information concerning an individual's health, biological relationships and hereditary characteristics.
Article 10 is particularly important because it regulates special categories of personal data, including health-related information.
Clinical sequencing therefore raises questions concerning:
Patient consent.
Lawful collection and processing.
Access restrictions.
Confidentiality.
Data security.
Disclosure to third parties.
Storage and deletion.
Cross-border transfers.
Genetic information may also concern relatives who have never undergone testing themselves.
Legal significance: A laboratory's permission to analyse a patient's DNA does not automatically establish unlimited permission to use the resulting genetic information for research, commercial development or unrelated investigations.
C. Ministry of Health Order No. 464n of 18 May 2021
This Order establishes rules for conducting laboratory investigations in medical organisations and other organisations performing medical activities under the relevant licences.
It covers clinical laboratory investigations and identifies laboratory genetics among the relevant licensed activities.
However, the Order expressly excludes certain genetic investigations concerning patients with congenital or hereditary diseases, which are regulated under the specific medical-care framework for such conditions.
The Order is therefore important but must not be incorrectly treated as the complete regulatory framework for all clinical genome sequencing.
Its stated period of operation runs from 1 September 2021 to 1 September 2027.
ГАРАНТ+1
D. GOST R ISO 15189-2024 – Medical Laboratory Quality and Competence
In force since 10 January 2025
This is one of the most important technical standards for clinical-grade sequencing laboratories in Russia.
It establishes requirements concerning:
Laboratory competence.
Personnel qualifications.
Equipment management.
Sample identification and traceability.
Analytical procedures.
Quality assurance.
Validation of examination methods.
Reporting of results.
Risk management.
Confidentiality of laboratory information.
The standard replaced GOST R ISO 15189-2015 and GOST R ISO 22870-2021.
Importantly, Order No. 309 of 14 May 2025 amended accreditation criteria under Order No. 707, incorporating GOST R ISO 15189-2024 into the requirements applicable to medical laboratories within the national accreditation system from 1 September 2025.
Росстандарт+2
E. Ministry of Health Order No. 193n of 19 March 2026
This is a significant recent development in Russian medical genetics.
It approves a model additional professional retraining programme in the specialty of Genetics.
The programme has a duration of 576 academic hours and addresses professional competencies including:
Diagnosis of congenital and hereditary diseases.
Medical and family-history assessment.
Molecular-genetic investigations.
Interpretation of laboratory results.
Selection of appropriate diagnostic investigations.
Clinical interpretation of hereditary variants.
Referral to relevant specialists.
This strengthens the professional training framework for medical geneticists.
However, it is a professional education instrument, not a technical certification standard for sequencing platforms.
rulaws.ru
3. Technical Standards for Clinical-Grade Genome Sequencing
Clinical-grade sequencing must satisfy scientific reliability requirements throughout the testing process.
The following stages are particularly important.
A. Pre-analytical standards
The pre-analytical stage concerns the collection, identification, transportation and preparation of biological samples.
Common samples include:
Blood.
Saliva.
Buccal swabs.
Tumour tissue.
Bone marrow.
Prenatal biological material.
A clinically reliable laboratory should establish procedures for:
Confirming patient identity.
Verifying the physician's test request.
Recording the source of the specimen.
Preventing sample contamination.
Maintaining appropriate transportation conditions.
Documenting sample receipt.
Recording rejection of unsuitable samples.
A sample-identification error can result in an incorrect genetic diagnosis being attributed to another patient.
Legal consequence: Where a laboratory's failure to identify a sample correctly causes harm, the matter may give rise to medical-service liability, contractual claims and compensation for injury.
B. Analytical sequencing standards
The analytical stage involves the actual examination of genetic material.
Clinical sequencing laboratories should establish validated procedures for:
DNA extraction.
DNA quality assessment.
Library preparation.
Sequencing-platform operation.
Read-depth assessment.
Coverage analysis.
Variant detection.
Variant confirmation where clinically indicated.
Detection of technical errors.
A sequencing platform should not be considered clinically reliable merely because it produces a large quantity of DNA data.
The laboratory must demonstrate that its method is suitable for the intended clinical purpose.
For example, a sequencing method validated for identifying single-nucleotide variants may not necessarily be sufficiently validated for detecting:
Large structural variants.
Copy-number variations.
Repeat expansions.
Complex rearrangements.
Mosaic variants.
Mitochondrial DNA abnormalities.
C. Analytical validation and verification
Validation establishes that a method is suitable for its intended use.
Verification establishes that an implemented method performs adequately under the laboratory's actual operating conditions.
A clinical laboratory should document relevant performance characteristics, including:
| Quality parameter | Clinical significance |
|---|---|
| Analytical sensitivity | Ability to detect relevant genetic variants |
| Analytical specificity | Ability to avoid false-positive results |
| Accuracy | Agreement with an appropriate reference method |
| Reproducibility | Consistency across repeated examinations |
| Coverage | Proportion of relevant genomic regions examined |
| Detection limits | Minimum variant level reliably detected |
| Contamination control | Prevention of misleading results |
| Sample identity | Assurance that the result belongs to the correct patient |
These are technical quality requirements and professional expectations, not a claim that Russian legislation prescribes one universal numerical threshold for every sequencing platform.
D. Bioinformatics and computational standards
Clinical genome sequencing depends heavily on computational analysis.
The process generally includes:
Sequence-read processing.
Alignment to a reference genome.
Variant calling.
Variant annotation.
Filtering of candidate variants.
Clinical classification.
Correlation with the patient's phenotype.
Preparation of the final report.
The laboratory should document its reference genome, software versions, databases, analytical pipelines and relevant changes.
A software update can affect variant identification and classification.
Consequently, laboratories must assess whether a change in the computational pipeline affects the reliability of previously validated procedures.
E. Variant classification
A clinically useful genome-sequencing report should distinguish between different levels of genetic significance.
A widely used scientific classification system recognises five categories:
| Classification | Meaning |
|---|---|
| Pathogenic | Strong evidence of disease causation |
| Likely pathogenic | Evidence strongly supports disease causation |
| Uncertain significance | Available evidence is insufficient |
| Likely benign | Evidence supports a non-disease-associated interpretation |
| Benign | Evidence supports a non-pathogenic interpretation |
A variant of uncertain significance (VUS) should not automatically be treated as a confirmed diagnosis.
For example, finding a VUS in a cancer-associated gene does not, by itself, establish that a patient has hereditary cancer syndrome.
Legal importance: A physician who treats an uncertain genetic finding as a definitive diagnosis without adequate clinical justification may face questions concerning professional negligence and the quality of medical care.
F. Post-analytical standards
The final stage includes interpretation, reporting, communication and clinical application.
A proper clinical sequencing report should ordinarily identify:
Patient and specimen identifiers.
Clinical indication.
Sequencing method.
Relevant technical limitations.
Genes and genomic regions examined.
Detected variants.
Variant classifications.
Relevant evidence supporting interpretation.
Recommendations for clinical correlation.
Limitations concerning negative findings.
Name and professional responsibility of the reporting specialist.
The report should distinguish between a negative result and the absence of a genetic disease.
A negative sequencing result does not necessarily exclude hereditary disease because some variants may remain undetected by the selected technology.
4. Clinical Accreditation and Laboratory Responsibility
Clinical-grade sequencing requires more than the purchase of a commercially available sequencing machine.
The laboratory must operate within the applicable medical licensing and quality-management framework.
Under the Russian accreditation framework, relevant responsibilities include:
1. Organisational responsibility: The laboratory must have an appropriate legal and operational structure.
2. Personnel responsibility: Staff must possess qualifications appropriate to their assigned work.
3. Equipment responsibility: Sequencing equipment must be appropriately maintained and monitored.
4. Methodological responsibility: Procedures must be documented and technically suitable.
5. Quality responsibility: The laboratory must monitor errors and investigate unreliable results.
6. Reporting responsibility: Results must be reviewed and communicated appropriately.
7. Information responsibility: Patient information must be protected against unauthorised access and disclosure.
GOST R ISO 15189-2024 is particularly relevant because it connects technical competence with the management of laboratory risks and the reliability of patient results.
ГАРАНТ+1
5. Informed Consent for Clinical Genome Sequencing
Informed consent is one of the most important legal requirements for clinical genome sequencing.
Article 20 of Federal Law No. 323-FZ requires informed voluntary consent before medical intervention, based on accessible information about its purposes, methods, risks, alternatives, consequences and expected results.
For genome sequencing, meaningful consent should address the particular features of genetic investigations.
These include:
The purpose and scope of sequencing.
Whether WGS, WES or targeted sequencing is being performed.
The possibility of identifying unexpected genetic findings.
The possibility of identifying hereditary disease risks.
Potential implications for biological relatives.
The limitations of genetic testing.
Whether additional testing may be required.
The handling and storage of biological samples.
Whether genetic data will be used for research.
Whether information may be shared with other healthcare professionals.
Article 13 protects medical confidentiality, including information obtained during medical examination and treatment.
Written consent is particularly important where medical confidentiality is to be waived for research, publication or other disclosure purposes.
Ministry of Health+1
Special issue: Incidental findings
Whole-genome sequencing can identify findings unrelated to the original medical question.
For example, a patient undergoing sequencing for an inherited neurological disorder might also receive an unexpected finding associated with hereditary cardiac disease.
This creates three legal questions:
Should the laboratory disclose the incidental finding?
Should the patient receive genetic counselling?
Can the information be communicated to relatives?
The appropriate approach involves the original consent, the clinical significance of the finding, professional responsibilities and applicable confidentiality rules.
A genetic laboratory should not assume that permission to investigate one disease creates unrestricted authority to disclose every finding to third parties.
6. Protection of Genetic Information and Data Security
Federal Law No. 152-FZ is central to the protection of genetic information.
Article 10 regulates special categories of personal data, including information about health.
Article 13 of Federal Law No. 323-FZ separately protects medical confidentiality.
Clinical genome sequencing creates particularly significant privacy concerns because genetic information can reveal information about:
Hereditary disorders.
Biological parentage.
Genetic relationships.
Predispositions to certain diseases.
Certain inherited characteristics.
Potential health risks affecting relatives.
A. Unauthorised disclosure
A laboratory may face legal consequences if genetic information is improperly disclosed to an employer, insurance organisation, commercial entity or unrelated third party.
B. Genetic databases
The use of genomic databases requires appropriate legal grounds and safeguards.
The laboratory should establish:
Access controls.
User authentication.
Secure storage.
Data-processing records.
Appropriate retention procedures.
Protection against unauthorised disclosure.
Procedures for handling data breaches.
C. Research and commercial reuse
A laboratory conducting clinical testing should distinguish between:
Clinical diagnosis.
Scientific research.
Pharmaceutical research.
Commercial genomic analysis.
Population-level genetic research.
Consent and legal authority for one purpose should not automatically be treated as permission for every other purpose.
D. Cross-border transfer
If genomic data is transferred to an overseas sequencing facility, cloud platform or research institution, the organisation must consider Russian personal-data legislation, including the applicable rules on international transfers and localisation.
This is particularly important where raw genomic files are transferred rather than only a limited clinical report.
rosguard.gov.ru+2
7. Medical Negligence and Clinical Sequencing Liability
Clinical genome sequencing creates several potential categories of professional and institutional liability.
A. Incorrect sequencing results
A laboratory may be responsible where a technical failure results in an incorrect clinical report.
Examples include:
Incorrect variant detection.
Failure to detect a clinically relevant variant because of inadequate validation.
Sample contamination.
Incorrect patient identification.
Incorrect interpretation of sequencing data.
B. Failure to identify clinically significant variants
A laboratory may face a negligence allegation where it fails to identify a clinically relevant variant that should reasonably have been detected using the validated method selected for the investigation.
However, not every missed variant establishes negligence.
The court would need to consider the method's technical limitations, the clinical indication, the available evidence and the professional standard applicable at the time.
C. Incorrect clinical interpretation
A sequencing laboratory and the treating physician may have different responsibilities.
For example:
The laboratory is responsible for the technical quality of its analysis and report.
The geneticist is responsible for appropriate clinical interpretation within their professional role.
The treating physician is responsible for considering the result in the context of the patient's overall medical condition.
Liability depends on the actual conduct of each participant.
D. Failure to disclose limitations
A report that presents a negative result without explaining important technical limitations may create a misleading impression.
For instance, a patient may believe that WGS excludes all hereditary causes of a disorder when the selected assay cannot reliably detect certain repeat expansions or complex structural variants.
E. Compensation and legal remedies
Potential legal routes include:
Civil claims for injury.
Claims concerning defective paid medical services.
Compensation for moral harm.
Regulatory investigation.
Professional disciplinary consequences where applicable.
Criminal proceedings where the statutory elements of an offence are established.
The existence of a poor sequencing result alone does not automatically establish criminal or civil liability. Breach, causation, harm and the applicable legal requirements must be proved.
8. Important Case Laws and Judicial Decisions
There is an important limitation in Russian genomic jurisprudence: there is no well-established body of Supreme Court decisions creating a comprehensive legal test specifically for clinical whole-genome sequencing quality.
Nevertheless, Russian judgments concerning genetic investigations, reproductive medicine and medical confidentiality provide important legal principles.
Case 1. Supreme Court of Russia – Civil Case No. 51-КГ19-7, 14 October 2019
Directly relevant Russian genetic-testing decision
Background
The dispute concerned the reimbursement of expenses for genetic examination of a child with a suspected hereditary condition.
A medical geneticist recommended genetic investigation, and the family subsequently arranged testing at a specialised laboratory.
The family incurred expenses for the examination and sought reimbursement.
Legal question
Whether the genetic examination could be considered part of medically necessary healthcare rather than simply an optional commercial service.
Decision
The Supreme Court upheld the conclusion supporting recovery of the expenses associated with the medically indicated genetic examination.
The Court's reasoning recognised the relevance of genetic investigations to the provision of medical assistance for a child with a disease.
ГАРАНТ
Legal principles
Genetic investigations may form part of medically necessary healthcare.
Medical necessity is relevant to the allocation of healthcare costs.
Genetic testing should be assessed in the context of the patient's medical condition.
A genetic examination cannot automatically be classified as a purely commercial service.
Relevance to clinical-grade sequencing
Although the dispute did not establish WGS-specific technical requirements, its reasoning is relevant to the legal status of medically indicated genetic testing.
It supports the argument that clinically necessary genomic investigations should be evaluated as part of healthcare delivery.
Case 2. Kalacheva v. Russia, Application No. 3451/05, Judgment of 7 May 2009
Russian DNA evidence case
Background
The applicant sought judicial recognition of paternity and child maintenance.
The domestic court ordered DNA testing. Blood samples were collected in Astrakhan and sent to a specialised institute in Moscow for forensic genetic examination.
The expert report indicated a 99.99% probability of paternity.
However, the domestic court rejected the applicant's claim after considering the available evidence and the disputed expert examination.
Legal question
The case concerned the effectiveness of the domestic judicial process in dealing with DNA evidence and the applicant's rights under the European Convention on Human Rights.
Decision
The European Court of Human Rights found a violation of Article 6 § 1 concerning the fairness of the proceedings.
HUDOC+1
Legal principles
DNA evidence can be highly important in determining biological relationships.
Courts must deal fairly with scientific evidence.
The procedural handling of genetic evidence matters.
Expert evidence should be considered in the context of the overall judicial process.
Relevance to genome sequencing
Modern clinical sequencing produces substantially more complex information than conventional paternity testing.
The reasoning in Kalacheva is relevant to questions concerning the admissibility, reliability and evaluation of genetic expert evidence.
It does not, however, establish clinical sequencing laboratory standards.
Case 3. Y.G. v. Russia, Application No. 8647/12, 30 August 2022
Important genetic-data privacy principle
Background
The applicant complained that confidential health information had not been adequately protected by the authorities.
The case concerned disclosure of health information through a database being sold in a market.
Legal question
Whether the Russian authorities had fulfilled their positive obligations to protect private medical information.
Decision
The European Court of Human Rights found a violation of Article 8 of the Convention.
It held that the authorities had failed to provide adequate protection for the applicant's health data and to investigate its disclosure effectively.
HUDOC
Legal principles
Health information requires effective confidentiality protection.
Authorities have positive obligations concerning personal medical information.
Unauthorised disclosure requires an effective response.
Privacy protection includes appropriate investigation of data leaks.
Relevance to clinical genome sequencing
A genome-sequencing report may contain significantly more hereditary information than an ordinary medical report.
The reasoning is relevant to the protection of raw sequencing files, genetic interpretations and patient-identifiable genomic databases.
Case 4. S. and Marper v. United Kingdom, Applications Nos. 30562/04 and 30566/04, Grand Chamber, 4 December 2008
Background
The applicants challenged the retention of fingerprints, cellular samples and DNA profiles after criminal proceedings had ended without conviction.
Legal question
Whether retaining biological samples and DNA profiles indefinitely interfered with the right to private life under Article 8.
Decision
The Grand Chamber found a violation of Article 8.
The Court emphasised the sensitive character of cellular samples and the genetic information they contain, including information relevant to health and biological relatives.
HUDOC+1
Legal principles
Genetic information is highly sensitive.
Biological samples can contain extensive personal information.
DNA information may reveal relationships between individuals.
Retention and processing of genetic material require appropriate safeguards.
Relevance to Russia
This is not a Russian domestic judgment. It is an important comparative European human-rights authority concerning DNA privacy.
It can inform legal analysis of genetic-data retention and confidentiality, although its criminal-justice context must be distinguished from clinical healthcare.
Important jurisdictional qualification: Russia ceased to be a party to the European Convention on Human Rights on 16 September 2022. The Convention remains relevant to the assessment of qualifying pre-withdrawal events, subject to the Court's temporal jurisdiction. Y.G. was decided in August 2022, before that date.
HUDOC+1
Case 5. Fourth Cassation Court of General Jurisdiction – Genetic Disease and Reproductive Medicine Dispute
Background
The dispute involved patients who received reproductive medical services and subsequently raised claims connected with the birth of a child with a genetic disease.
The litigation concerned whether the medical organisation had provided appropriate services and whether additional genetic investigations or genetic counselling were required.
Legal question
Whether the medical organisation had breached its contractual or professional responsibilities in the provision of reproductive medical services.
Judicial significance
The Fourth Cassation Court identified procedural defects in the earlier proceedings, including the failure to involve the prosecutor where required, and the case was reconsidered under the appropriate procedural rules.
The underlying dispute also involved expert assessment of the scope of the medical services contracted for and whether additional genetic investigations were medically indicated.
4kas.sudrf.ru+1
Relevance to clinical genome sequencing
This dispute illustrates why the scope of medical contracts, genetic counselling, the clinical indication for testing and expert evidence matter when assessing liability in reproductive genetics.
It does not establish a universal duty to perform genome sequencing in every reproductive-medicine case.
9. International Scientific Standards and Their Relevance to Russia
Although Russian law provides its own regulatory framework, internationally recognised scientific standards are useful for evaluating the quality of clinical sequencing.
| International framework | Relevance |
|---|---|
| ISO 15189:2022 | Medical laboratory quality and competence |
| ISO 17025 | Testing and calibration laboratory competence |
| ACMG/AMP variant interpretation framework | Classification of genetic variants |
| ClinGen recommendations | Evidence-based clinical interpretation |
| HGVS nomenclature | Standardised description of genetic variants |
| Human Genome Variation Society recommendations | Consistent genetic reporting |
| GA4GH frameworks | Responsible genomic-data sharing |
These frameworks should not all be described as independently binding Russian laws.
Their legal relevance depends on incorporation into applicable standards, laboratory procedures, contracts, accreditation requirements or professional evidence.
In particular, GOST R ISO 15189-2024 is the relevant Russian national medical-laboratory standard, while international variant-classification recommendations provide scientific methods for interpreting genetic findings.
10. Major Legal Challenges in Clinical-Grade Sequencing
A. Absence of a single genome-sequencing statute
Russia's regulatory framework is distributed across medical, laboratory, professional and data-protection legislation.
This can create uncertainty regarding specialised WGS quality requirements.
B. Inconsistent interpretation of genetic variants
Different laboratories may classify the same genetic variant differently because of differences in databases, analytical pipelines or available scientific evidence.
C. Responsibility for bioinformatics errors
It may be difficult to identify whether an incorrect result originated from sequencing equipment, software, variant annotation or clinical interpretation.
D. Long-term genomic-data retention
Genome sequencing creates data that may remain scientifically relevant for decades.
The legal challenge is balancing clinical usefulness against confidentiality, security and legitimate retention requirements.
E. Genetic information affecting relatives
A patient's sequencing results may reveal hereditary risks affecting other family members.
This creates difficult questions concerning confidentiality and the appropriate communication of clinically significant findings.
F. Reanalysis of historical genomic data
Scientific knowledge changes over time. A previously uncertain variant may later be classified as pathogenic.
Russian law must therefore be applied alongside appropriate professional policies concerning reanalysis, communication and responsibility for updated findings.
G. Artificial intelligence in genomic interpretation
AI-assisted sequencing interpretation raises questions concerning:
Algorithmic transparency.
Validation of automated systems.
Human review.
Explainability of clinical conclusions.
Accountability for incorrect recommendations.
Protection of genomic data.
The use of an AI system does not eliminate the legal responsibilities of the medical organisation and relevant healthcare professionals.
11. Recommended Compliance Framework for Russian Clinical Sequencing Laboratories
A practical compliance system should include the following measures.
Clinical genome sequencing compliance checklist
Recommended operational framework, not a verbatim statutory checklist.
Implementation progress
0/12
Verify the appropriate medical licence and scope of laboratory activity.
Establish patient identification and specimen-traceability procedures.
Obtain and document informed voluntary consent.
Validate sequencing methods for their intended clinical applications.
Document sequencing equipment and bioinformatics pipelines.
Establish variant classification and review procedures.
Maintain internal quality control and external quality assessment where available.
Provide clinically interpretable reports with technical limitations.
Protect genomic information under applicable data-protection and medical-confidentiality laws.
Establish procedures for incidental findings and genetic counselling.
Maintain procedures for data retention, reanalysis and authorised disclosure.
Investigate and document laboratory errors and adverse incidents.
12. Conclusion
Clinical-grade genome sequencing in Russia is governed by a combination of healthcare legislation, medical laboratory regulations, national quality standards, professional requirements and personal-data protection rules.
The most important instruments include:
Federal Law No. 323-FZ of 2011.
Federal Law No. 152-FZ of 2006.
Ministry of Health Order No. 464n of 2021.
GOST R ISO 15189-2024.
Ministry of Economic Development Order No. 707, as amended.
Ministry of Health Order No. 193n of 2026.
The judicial authorities have also developed relevant principles concerning genetic testing, medical confidentiality, scientific evidence and medical-service liability.
The Supreme Court's decision in Case No. 51-КГ19-7 is particularly important for the recognition of medically indicated genetic investigations as part of healthcare. Kalacheva v. Russia provides guidance on the judicial treatment of DNA evidence, while Y.G. v. Russia demonstrates the importance of protecting confidential health information.
The central legal principle is that clinical-grade genome sequencing must be scientifically reliable, medically justified, professionally interpreted and legally protected. A sequencing result should not be treated as a definitive clinical diagnosis unless its technical reliability and clinical significance have been appropriately established.
13. Principal Legal and Regulatory References
| Reference | Subject |
|---|---|
| Federal Law 323-FZ (2011) | Healthcare rights and medical confidentiality |
| Federal Law 152-FZ (2006) | Personal-data protection |
| Order 464n (2021) | Laboratory investigations |
| GOST R ISO 15189-2024 | Medical laboratory quality |
| Order 707 (2020), as amended | Accreditation criteria |
| Order 193n (2026) | Professional retraining in genetics |
| Case 51-КГ19-7 (2019) | Medical genetic examination expenses |
| Kalacheva v. Russia (2009) | DNA evidence and fair proceedings |
| Y.G. v. Russia (2022) | Confidentiality of health information |
| S. and Marper v. UK (2008) | DNA privacy and retention |
Primary research sources
Russian Ministry of Health – Federal Law 323-FZ.
Federal Law 152-FZ – Personal Data.
Ministry of Health Order 464n.
GOST R ISO 15189-2024 – Rosstandart.
Ministry of Health Order 193n of 2026.
Russian Supreme Court – Case 51-КГ19-7.
Y.G. v. Russia – ECHR judgment.
Research qualification: This is a legal and academic overview, not a claim that Russia has adopted every international genomic laboratory recommendation as a binding statutory requirement. The precise obligations should be checked against the current consolidated legislation and the particular laboratory's licensed activities.

comments